Repertoization Team: Kate Birch, RSHom(NA), CCH, C.HPx, Jiuan Heng, CCH, RSHom(NA), C.HPx, Crystal Morse, BCN, DNM, C.HPx, Shelly Garrison, CCH, C.HPx, Cheryl Wood, CCH, RSHom(NA), C.HPx, Gabriella Calvi-Rooney, B.S., DSH, C.HP,x Ursula Dobelmann, CCH, C.HP.x.

 

Source: Coronavirus was first identified in Wuhan, China, in December 2019. Thirteen samples were shipped to a third-party lab in the US for authentication. The nosode, Novus-CV, was made from samples that passed authentication. The samples were from nasopharyngeal swabs, alveolar lavage fluid, and sputum of active human cases of CV. This is a nosode made from the mutated form of the virus; one that has been passed from human to human. The nosode was potentized in the traditional way of trituration, dilution, and succussion.

Clinical presentation of Covid-19 and immunological symptoms

The clinical presentation of Covid-19 includes fever and/or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting and diarrhea. In that order of prevalence.[i]

Proving structure:

FHCi used the 1M potency for research purposes to determine the safety, effects, and efficacy of this nosode in humans for coronavirus disease prevention and treatment. The proving symptoms collated below are the cured and induced symptoms after a single dose (three pellets) of the 1M potency, followed a week later by a triple dose: 3 times in one day. A two-week follow-up questionnaire was sent to registrants to determine remedy response and symptom presentation. The subjective reports of symptoms during the FHCI 2020 research were used to evaluate the collective symptom presentation. 63 registrants had active disease and 17 had unresolved long-term covid-19 like disease expression upon registration. Some of the symptoms recorded are cured symptoms. See full research links at the end of this paper.